Compare HUBS & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUBS | PTGX |
|---|---|---|
| Founded | 2005 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5B | 8.5B |
| IPO Year | 2014 | 2016 |
| Metric | HUBS | PTGX |
|---|---|---|
| Price | $217.09 | $138.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 32 | 13 |
| Target Price | ★ $435.19 | $108.23 |
| AVG Volume (30 Days) | ★ 1.3M | 761.7K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 855.56 | N/A |
| EPS | ★ 0.62 | 0.05 |
| Revenue | ★ $375,612,000.00 | N/A |
| Revenue This Year | $20.46 | $874.25 |
| Revenue Next Year | $16.01 | N/A |
| P/E Ratio | ★ $374.90 | $2,685.40 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $169.63 | $50.49 |
| 52 Week High | $568.16 | $143.29 |
| Indicator | HUBS | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 57.26 | 61.49 |
| Support Level | $209.40 | $94.48 |
| Resistance Level | $225.58 | $141.10 |
| Average True Range (ATR) | 12.55 | 6.64 |
| MACD | 3.71 | -0.42 |
| Stochastic Oscillator | 69.59 | 68.67 |
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.